Valuation: Larimar Therapeutics, Inc.

Market Cap 237M 212M 195M 177M 333M 22.44B 338M 2.35B 926M 11.76B 889M 870M 37.25B P/E 2026 *
-1.71x
P/E 2027 * -1.93x
Enterprise Value 149M 133M 123M 112M 209M 14.14B 213M 1.48B 583M 7.41B 560M 548M 23.46B EV / Sales 2026 *
-
EV / Sales 2027 * 5.68x
Free-Float
98.81%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day-6.20%
1 week+14.07%
Current month-28.95%
1 month-40.58%
3 months-43.53%
6 months-50.22%
Current year-40.42%
1 week 1.96
Extreme 1.96
2.54
1 month 1.92
Extreme 1.915
3.86
Current year 1.92
Extreme 1.915
6.42
1 year 1.92
Extreme 1.915
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
13.68
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 30/04/2020
President 50 28/09/2026
Director of Finance/CFO 67 27/05/2020
Director TitleAgeSince
Director/Board Member 67 31/12/2019
Chairman 61 27/05/2020
Director/Board Member 58 27/05/2020
Date Insider Type Main position Quantity % Market Cap. Importance
29/09/26 Free

Chairperson

850,000 0.9931%
06/07/26 Buy

Director

50,000 0.0584%
19/05/26 Free

Director

55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
-6.20%+14.07%-42.24%-22.26% 237M
-4.10%-8.54%+40.05%+66.99% 63.29B
+0.05%+7.72%+11.24%+73.83% 54.89B
+0.38%+4.40%+9.86%+92.49% 53.28B
+0.61%+2.69%+27.75%+50.97% 45.81B
-1.08%+2.19%+21.92%+131.38% 43.46B
-3.39%-0.83%+254.27%+571.04% 40.23B
-1.67%+6.70%+14.42%+56.67% 33.45B
+1.19%-4.98%+29.01%-0.76% 23.7B
-0.79%+5.16%+35.76%+26.92% 23.76B
Average -1.51%+1.82%+40.20%+104.73% 38.21B
Weighted average by Cap. -1.16%+0.60%+47.47%+122.35%

Financials

2026 *2027 *
Net sales - 41.74M 37.25M 34.37M 31.23M 58.58M 3.95B 59.48M 414M 163M 2.07B 157M 153M 6.56B
Net income -137M -122M -113M -103M -192M -12.98B -195M -1.36B -535M -6.8B -514M -503M -21.54B -155M -138M -128M -116M -218M -14.69B -221M -1.54B -606M -7.7B -582M -570M -24.38B
Net Debt -87.7M -78.28M -72.22M -65.61M -123M -8.31B -125M -870M -343M -4.35B -329M -322M -13.79B -
Projected Income Statement - Annual - Larimar Therapeutics, Inc.
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
22/10/26 US$2.270 -6.20% 1,763,899
21/10/26 US$2.420 -0.82% 1,512,896
20/10/26 US$2.440 +15.09% 1,810,765
19/10/26 US$2.120 +6.80% 1,231,361
16/10/26 US$1.985 -0.25% 1,691,973
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Larimar Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.270USD
Average target price
14.40USD
Spread / Average Target
+534.36%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Larimar Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LRMR Stock